MADISON, WI USA (June 24, 2026) Porta Sophia filed a third-party preissuance submission with the United States Patent and Trademark Office (USPTO) today for U.S. Pat. App. Ser. No. 19/310,559 entitled “METHODS OF USING DMT”, which is currently assigned to William Shulman. The submission consisted of three prior art documents that are material to the patentability of one claim of the application.
Porta Sophia, a non-profit psychedelic prior art library, leverages the experience of legal and interdisciplinary academic scholars to promote an ethical psychedelic patenting landscape that preserves the integrity of the public domain. The organization curates and makes relevant historical documentation readily available for anyone wanting to explore the scope of psychedelic technologies, including patent examiners.
Patent application: DMT use and administration
The ’559 application was filed on August 26, 2025 and claims priority to a provisional application filed on March 9, 2023. It describes the administration of a long-acting tryptamine prior to DMT to enhance the DMT experience.
Prior art in the third-party preissuance submission included publications from web pages and a peer reviewed journal. This prior art anticipates claims in the ’559 application. The full third-party submission documentation is available here.
Third-party submissions of prior art
United States patent law allows third parties to submit prior art and concise descriptions of their relevance to the USPTO. Documents submitted may be considered in the examination of that patent application. In addition, these submissions have a broad impact because applicants have a duty to disclose the prior art submitted against a single patent application for other relevant patent applications filed by the applicant.
Porta Sophia tracks and analyzes psychedelic patent applications globally. If an application improperly claims innovation of something known in the public domain and meets the standards of Porta Sophia's third party intervention evaluation criteria, the team assembles evidence against these invalid claims and contests them directly to the relevant patent office through third-party interventions.
View Our Summary Chart